REGENXBIO Company Profile (NASDAQ:RGNX)

About REGENXBIO (NASDAQ:RGNX)

REGENXBIO logoREGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RGNX
  • CUSIP: N/A
  • Web: www.regenxbio.com
Capitalization:
  • Market Cap: $899.07 million
  • Outstanding Shares: 30,894,000
Average Prices:
  • 50 Day Moving Avg: $27.39
  • 200 Day Moving Avg: $27.39
  • 52 Week Range: $13.61 - $30.25
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.13
  • P/E Growth: 0.33
Sales & Book Value:
  • Annual Revenue: $8.84 million
  • Price / Sales: 102.40
  • Book Value: $6.86 per share
  • Price / Book: 4.27
Profitability:
  • EBIDTA: ($75,420,000.00)
  • Net Margins: -839.87%
  • Return on Equity: -38.74%
  • Return on Assets: -36.33%
Debt:
  • Current Ratio: 14.47%
  • Quick Ratio: 14.47%
Misc:
  • Average Volume: 369,643 shs.
  • Beta: -0.87
  • Short Ratio: 7.03
 

Frequently Asked Questions for REGENXBIO (NASDAQ:RGNX)

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.81) by $0.34. The company earned $6.56 million during the quarter. REGENXBIO had a negative return on equity of 38.74% and a negative net margin of 839.87%. View REGENXBIO's Earnings History.

When will REGENXBIO make its next earnings announcement?

REGENXBIO is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for REGENXBIO.

Where is REGENXBIO's stock going? Where will REGENXBIO's stock price be in 2017?

4 brokers have issued 1 year price targets for REGENXBIO's shares. Their forecasts range from $25.00 to $75.00. On average, they anticipate REGENXBIO's share price to reach $39.50 in the next year. View Analyst Ratings for REGENXBIO.

Who are some of REGENXBIO's key competitors?

Who are REGENXBIO's key executives?

REGENXBIO's management team includes the folowing people:

  • Donald J. Hayden Jr., Independent Chairman of the Board
  • Kenneth T. Mills, President, Chief Executive Officer, Executive Director
  • Vittal K. Vasista, Chief Financial Officer
  • Patrick J. Christmas, Senior Vice President, General Counsel
  • Curran M. Simpson, Senior Vice President - Technical Operations
  • Olivier Danos Ph.D., Chief Scientific Officer
  • Faraz Ali, Chief Business Officer
  • Stephen Yoo M.D., Chief Medical Officer
  • Allan M. Fox, Director
  • Daniel J. Abdun-Nabi, Independent Director

Who owns REGENXBIO stock?

REGENXBIO's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (7.37%), Bain Capital Public Equity Management LLC (5.70%), Redmile Group LLC (5.56%), JPMorgan Chase & Co. (3.98%), Vanguard Group Inc. (3.51%) and Citadel Advisors LLC (3.01%). Company insiders that own REGENXBIO stock include Donald J Hayden Jr, Fmr Llc, James E Flynn, Kenneth T Mills, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for REGENXBIO.

Who sold REGENXBIO stock? Who is selling REGENXBIO stock?

REGENXBIO's stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, Bain Capital Public Equity Management LLC, Franklin Resources Inc., EAM Investors LLC, Russell Investments Group Ltd., FMR LLC, Fernwood Investment Management LLC and Victory Capital Management Inc.. Company insiders that have sold REGENXBIO stock in the last year include Donald J Hayden Jr, Kenneth T Mills, Stephen Yoo and Vittal Vasista. View Insider Buying and Selling for REGENXBIO.

Who bought REGENXBIO stock? Who is buying REGENXBIO stock?

REGENXBIO's stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, GMT Capital Corp, Redmile Group LLC, Citadel Advisors LLC, Botty Investors LLC, Vanguard Group Inc., Laurion Capital Management LP and Northern Trust Corp. View Insider Buying and Selling for REGENXBIO.

How do I buy REGENXBIO stock?

Shares of REGENXBIO can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is REGENXBIO's stock price today?

One share of REGENXBIO stock can currently be purchased for approximately $29.30.


MarketBeat Community Rating for REGENXBIO (NASDAQ RGNX)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  93 (Vote Outperform)
Underperform Votes:  90 (Vote Underperform)
Total Votes:  183
MarketBeat's community ratings are surveys of what our community members think about REGENXBIO and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for REGENXBIO (NASDAQ:RGNX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $39.50 (34.81% upside)

Analysts' Ratings History for REGENXBIO (NASDAQ:RGNX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/21/2017Bank of America CorporationBoost Price TargetBuy$29.00 -> $33.00LowView Rating Details
9/5/2017Chardan CapitalReiterated RatingBuy$55.00 -> $75.00HighView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$25.00HighView Rating Details
11/13/2016Piper Jaffray CompaniesReiterated RatingBuy$25.00N/AView Rating Details
4/8/2016Morgan StanleyBoost Price Target$34.00 -> $36.00N/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for REGENXBIO (NASDAQ:RGNX)
Earnings by Quarter for REGENXBIO (NASDAQ:RGNX)
Earnings History by Quarter for REGENXBIO (NASDAQ RGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.73)N/AView Earnings Details
8/8/2017Q2 2017($0.81)($0.47)$6.56 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.76)($0.82)$0.46 millionViewListenView Earnings Details
3/7/2017Y 2016($0.75)($0.74)$1.70 millionViewListenView Earnings Details
5/5/2016($0.40)($0.41)$0.39 millionViewN/AView Earnings Details
3/3/2016Q415($0.34)($0.20)$1.23 million$4.40 millionViewN/AView Earnings Details
11/5/2015Q315($0.35)($1.52)$1.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for REGENXBIO (NASDAQ:RGNX)
Current Year EPS Consensus Estimate: $-2.74 EPS
Next Year EPS Consensus Estimate: $-3.21 EPS

Dividends

Dividend History for REGENXBIO (NASDAQ:RGNX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for REGENXBIO (NASDAQ:RGNX)
Insider Ownership Percentage: 17.00%
Institutional Ownership Percentage: 73.23%
Insider Trades by Quarter for REGENXBIO (NASDAQ:RGNX)
Institutional Ownership by Quarter for REGENXBIO (NASDAQ:RGNX)
Insider Trades by Quarter for REGENXBIO (NASDAQ:RGNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/18/2017Donald J Hayden JrDirectorSell40,000$28.70$1,148,000.00View SEC Filing  
9/15/2017Vittal VasistaCFOSell5,000$27.39$136,950.00View SEC Filing  
9/8/2017Stephen YooInsiderSell27,342$25.00$683,550.00View SEC Filing  
9/6/2017Stephen YooInsiderSell32,658$25.00$816,450.00View SEC Filing  
9/5/2017Donald J Hayden JrDirectorSell20,000$24.95$499,000.00View SEC Filing  
9/5/2017Kenneth T MillsInsiderSell10,500$25.00$262,500.00View SEC Filing  
8/21/2017Kenneth T MillsInsiderSell6,500$20.05$130,325.00View SEC Filing  
8/15/2017Vittal VasistaCFOSell3,040$21.09$64,113.60View SEC Filing  
7/20/2017Kenneth T MillsInsiderSell6,500$18.66$121,290.00View SEC Filing  
7/17/2017Vittal VasistaCFOSell3,100$19.81$61,411.00View SEC Filing  
6/20/2017Kenneth T MillsInsiderSell6,500$19.68$127,920.00View SEC Filing  
6/15/2017Vittal VasistaCFOSell3,100$18.75$58,125.00View SEC Filing  
4/24/2017Donald J Hayden JrDirectorSell10,000$20.98$209,800.00View SEC Filing  
4/24/2017Kenneth T MillsInsiderSell15,440$20.98$323,931.20View SEC Filing  
4/24/2017Vittal VasistaCFOSell3,100$21.00$65,100.00View SEC Filing  
5/17/2016Fmr LlcInsiderSell18,300$12.41$227,103.00View SEC Filing  
5/16/2016Fmr LlcInsiderSell16,030$11.65$186,749.50View SEC Filing  
5/12/2016Fmr LlcInsiderSell6,711$10.85$72,814.35View SEC Filing  
5/11/2016Fmr LlcInsiderSell25,132$10.36$260,367.52View SEC Filing  
5/9/2016Fmr LlcInsiderSell10,570$9.94$105,065.80View SEC Filing  
5/4/2016Fmr LlcInsiderSell1,896$10.51$19,926.96View SEC Filing  
5/3/2016Fmr LlcInsiderSell6,046$10.76$65,054.96View SEC Filing  
4/29/2016Fmr LlcInsiderSell4,723$10.80$51,008.40View SEC Filing  
4/28/2016Fmr LlcInsiderSell33,196$11.23$372,791.08View SEC Filing  
4/26/2016Fmr LlcInsiderSell9,188$11.19$102,813.72View SEC Filing  
4/22/2016Fmr LlcInsiderSell20,558$11.30$232,305.40View SEC Filing  
4/20/2016Fmr LlcInsiderSell13,189$11.66$153,783.74View SEC Filing  
4/18/2016Fmr LlcInsiderSell18,900$11.75$222,075.00View SEC Filing  
4/14/2016Fmr LlcInsiderSell27,036$11.46$309,832.56View SEC Filing  
9/22/2015James E FlynnInsiderBuy175,000$22.00$3,850,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for REGENXBIO (NASDAQ:RGNX)
Latest Headlines for REGENXBIO (NASDAQ:RGNX)
Source:
DateHeadline
americanbankingnews.com logoREGENXBIO Inc. (RGNX) Price Target Increased to $33.00 by Analysts at Bank of America Corporation
www.americanbankingnews.com - September 21 at 10:54 AM
streetinsider.com logoUltragenyx Pharma (RARE) Offers to Acqurie Dimension Therapeutics (DMTX) for $5.50/Share
www.streetinsider.com - September 20 at 8:23 AM
finance.yahoo.com logoREGENXBIO Announces Completion of Dosing of First Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD
finance.yahoo.com - September 20 at 8:23 AM
americanbankingnews.com logoREGENXBIO Inc. (RGNX) CFO Vittal Vasista Sells 5,000 Shares
www.americanbankingnews.com - September 19 at 8:10 PM
americanbankingnews.com logoREGENXBIO Inc. (RGNX) Director Donald J. Hayden, Jr. Sells 40,000 Shares
www.americanbankingnews.com - September 19 at 7:24 PM
americanbankingnews.com logoREGENXBIO Inc. (RGNX) Insider Stephen Yoo Sells 27,342 Shares
www.americanbankingnews.com - September 12 at 7:34 PM
americanbankingnews.com logoZacks: Brokerages Expect REGENXBIO Inc. (RGNX) Will Announce Earnings of -$0.74 Per Share
www.americanbankingnews.com - September 12 at 8:26 AM
americanbankingnews.com logoREGENXBIO Inc. (RGNX) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 10 at 2:42 AM
americanbankingnews.com logoREGENXBIO Inc. (RGNX) Insider Kenneth T. Mills Sells 10,500 Shares
www.americanbankingnews.com - September 7 at 7:42 PM
americanbankingnews.com logoDonald J. Hayden, Jr. Sells 20,000 Shares of REGENXBIO Inc. (RGNX) Stock
www.americanbankingnews.com - September 7 at 7:42 PM
americanbankingnews.com logoStephen Yoo Sells 32,658 Shares of REGENXBIO Inc. (RGNX) Stock
www.americanbankingnews.com - September 7 at 7:20 PM
americanbankingnews.com logoREGENXBIO Inc. (RGNX) Receives Buy Rating from Chardan Capital
www.americanbankingnews.com - September 5 at 8:28 PM
americanbankingnews.com logoComparing Intra-Cellular Therapies (ITCI) & REGENXBIO (RGNX)
www.americanbankingnews.com - September 1 at 9:03 AM
finance.yahoo.com logoREGENXBIO to Present at Upcoming Investor Conferences
finance.yahoo.com - August 31 at 9:25 AM
finance.yahoo.com logoDIMENSION THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dimension Therapeutics, Inc.
finance.yahoo.com - August 29 at 3:15 PM
bizjournals.com logoGene therapy firm sold
www.bizjournals.com - August 25 at 10:52 AM
rttnews.com logoDimension Therapeutics Inc. (DMTX) Is Up Sharply After Bought By REGENXBIO
www.rttnews.com - August 25 at 10:52 AM
streetinsider.com logoRegenxbio (RGNX) to Acquire Dimension Therapeutics (DMTX) in All-Stock Transaction
www.streetinsider.com - August 25 at 10:52 AM
finance.yahoo.com logoREGENXBIO to Acquire Dimension Therapeutics
finance.yahoo.com - August 25 at 10:52 AM
finance.yahoo.com logoCambridge gene therapy firm Dimension Therapeutics to be acquired
finance.yahoo.com - August 25 at 10:52 AM
americanbankingnews.com logo Analysts Expect REGENXBIO Inc. (RGNX) Will Announce Earnings of -$0.74 Per Share
www.americanbankingnews.com - August 24 at 8:32 PM
americanbankingnews.com logoREGENXBIO Inc. (RGNX) Insider Kenneth T. Mills Sells 6,500 Shares
www.americanbankingnews.com - August 23 at 8:04 PM
americanbankingnews.com logoZacks Investment Research Downgrades Regenxbio Inc (RGNX) to Hold
www.americanbankingnews.com - August 20 at 7:32 PM
americanbankingnews.com logoREGENXBIO Inc. (RGNX) CFO Vittal Vasista Sells 3,040 Shares
www.americanbankingnews.com - August 17 at 8:50 PM
americanbankingnews.com logoREGENXBIO Inc. (RGNX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 16 at 6:32 PM
americanbankingnews.com logoEvercore ISI Initiates Coverage on REGENXBIO Inc. (RGNX)
www.americanbankingnews.com - August 16 at 6:26 PM
americanbankingnews.com logo REGENXBIO Inc. (RGNX) Given $38.67 Average Price Target by Brokerages
www.americanbankingnews.com - August 14 at 6:16 AM
americanbankingnews.com logoREGENXBIO Inc. (NASDAQ:RGNX) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - August 12 at 5:42 PM
americanbankingnews.com logoBidaskClub Upgrades REGENXBIO Inc. (RGNX) to Buy
www.americanbankingnews.com - August 12 at 1:08 PM
nasdaq.com logoREGENXBIO to Present on RGX-314 Gene Therapy Program for Wet AMD at 35th Annual Scientific Meeting of the American Society of Retina Specialists
www.nasdaq.com - August 12 at 7:22 AM
finance.yahoo.com logoREGENXBIO, Inc. breached its 50 day moving average in a Bullish Manner : RGNX-US : August 10, 2017
finance.yahoo.com - August 11 at 8:02 AM
finance.yahoo.com logoREGENXBIO Reports Second Quarter 2017 Financial Results and Recent Operational Highlights
finance.yahoo.com - August 9 at 6:56 AM
finance.yahoo.com logoEdited Transcript of RGNX earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 9 at 6:56 AM
americanbankingnews.com logoREGENXBIO Inc. (RGNX) Posts Quarterly Earnings Results, Beats Expectations By $0.34 EPS
www.americanbankingnews.com - August 8 at 9:30 PM
americanbankingnews.com logoREGENXBIO Inc. (NASDAQ:RGNX) Expected to Announce Earnings of -$0.81 Per Share
www.americanbankingnews.com - August 6 at 10:26 AM
americanbankingnews.com logoREGENXBIO Inc. (RGNX) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 3 at 11:28 AM
finance.yahoo.com logoREGENXBIO to Host Conference Call on August 8 to Discuss Second Quarter 2017 Financial Results and Recent Operational Highlights
finance.yahoo.com - August 2 at 7:10 AM
finance.yahoo.com logoREGENXBIO, Inc. – Value Analysis (NASDAQ:RGNX) : August 1, 2017
finance.yahoo.com - August 2 at 7:10 AM
americanbankingnews.com logoREGENXBIO (NASDAQ:RGNX) vs. Sarepta Therapeutics (SRPT) Financial Survey
www.americanbankingnews.com - July 30 at 12:21 AM
americanbankingnews.com logo REGENXBIO Inc. (RGNX) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - July 27 at 11:22 AM
americanbankingnews.com logoREGENXBIO Inc. (NASDAQ:RGNX) Insider Kenneth T. Mills Sells 6,500 Shares
www.americanbankingnews.com - July 24 at 7:50 PM
finance.yahoo.com logoREGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : July 19, 2017
finance.yahoo.com - July 20 at 7:11 AM
americanbankingnews.com logoREGENXBIO Inc. (RGNX) CFO Sells $61,411.00 in Stock
www.americanbankingnews.com - July 19 at 8:00 PM
americanbankingnews.com logo-$0.81 Earnings Per Share Expected for REGENXBIO Inc. (RGNX) This Quarter
www.americanbankingnews.com - July 17 at 10:57 AM
finance.yahoo.com logoREGENXBIO to Participate in the Piper Jaffray GenomeRx Symposium
finance.yahoo.com - July 7 at 8:22 AM
americanbankingnews.com logoInsider Selling: REGENXBIO Inc. (RGNX) Insider Sells 6,500 Shares of Stock
www.americanbankingnews.com - June 22 at 7:48 PM
finance.yahoo.com logoREGENXBIO, Inc. breached its 50 day moving average in a Bullish Manner : RGNX-US : June 21, 2017
finance.yahoo.com - June 22 at 10:44 AM
americanbankingnews.com logo Brokerages Set $37.00 Target Price for REGENXBIO Inc. (RGNX)
www.americanbankingnews.com - June 21 at 6:32 PM
americanbankingnews.com logoREGENXBIO Inc. (RGNX) Expected to Announce Earnings of -$0.81 Per Share
www.americanbankingnews.com - June 21 at 7:34 AM
americanbankingnews.com logoREGENXBIO Inc. (RGNX) CFO Sells $58,125.00 in Stock
www.americanbankingnews.com - June 19 at 7:56 PM

Social

Chart

REGENXBIO (RGNX) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff